February 27, 2014
This article was reported by Healio.
Healio reported on a study that concluded that individuals with hepatitis C virus (HCV) infection had a higher risk of dying and of dying prematurely compared with the general population. Researchers analyzed New York City Department of Health and Mental Hygiene surveillance and mortality data from 2000 to 2010, including factors associated with mortality and causes of mortality among individuals with HCV.
Results show that from 2000 to 2010, the department recorded 128,444 HCV infections, which included 18,291 individuals with HIV coinfection. Of the patients with HCV only, 13,307 died between 2000 and 2011, and 8,525 of them died prematurely; 5,475 persons with HIV/HCV coinfection died during this time, and 94 percent of them died prematurely. Of the general public, 619,254 adults who were uninfected with either of the two diseases died, and 25.3 percent of them died prematurely. Median age of death for individuals with HCV only was 60 years, compared with 78 years for individuals without any infection, and 52 years for adults with HIV/HCV coinfection.
The researchers emphasized the value of identifying and treating HCV infection, reducing new infections, and preventing drug-related deaths using harm reduction methods to decrease the number of premature deaths and HCV treatment costs.
The full report, "Deaths Among People with Hepatitis C in New York City, 2000-2011," was published online in the journal Clinical Infectious Diseases (2014; doi:10.1093/cid/ciu075).
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Long-Acting HIV Treatment: 5 Myths and Realities|
|Two-Drug HIV Treatment Regimens Effective in Latest Studies|
|The Need to Advocate for Fair HIV Drug Prices|
|'Stop Describing, Start Intervening': Can the CDC's New Viral Load Data Help Guide HIV Programs?|
|IL-1β Inhibitor Lowers Arterial Inflammation in Adults With Controlled HIV|
|Significant Interaction Between Once-Weekly Isoniazid/Rifapentine and Daily Dolutegravir: Study Stopped Due to Toxicity|